eli lilly clinical trials retatrutide Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Eli Lilly's trial of obesity

CNTs, cylindrical tubes formed from rolled graphene, hold promise in strategies enhancing the immune response in cancer treatment due to their immunostimulatory potential

Our findings suggest that tirzepatide, through its dual GIP/GLP-1 action, may be superior as a non-IOPlowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes, the researchers wrote in their paper

Adults have a relatively stable gut microbiota, but long-term dietary changes, medication use, and other diseases can have a disruptive effect

In its standard oral form, it is often broken down by stomach acid before it ever reaches your cells